These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26961297)

  • 1. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials.
    Santangeli P; Muser D; Maeda S; Filtz A; Zado ES; Frankel DS; Dixit S; Epstein AE; Callans DJ; Marchlinski FE
    Heart Rhythm; 2016 Jul; 13(7):1552-9. PubMed ID: 26961297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Recurrent Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators-A Network Meta-analysis.
    Malik AH; Aronow WS
    Am J Ther; 2019; 26(4):e469-e480. PubMed ID: 30946044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kheiri B; Barbarawi M; Zayed Y; Hicks M; Osman M; Rashdan L; Kyi HH; Bachuwa G; Hassan M; Stecker EC; Nazer B; Bhatt DL
    Circ Arrhythm Electrophysiol; 2019 Nov; 12(11):e007600. PubMed ID: 31698933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?].
    Tanner H; Hindricks G; Kottkamp H
    Herz; 2005 Nov; 30(7):613-8. PubMed ID: 16333587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
    Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
    Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial.
    Al-Khatib SM; Daubert JP; Anstrom KJ; Daoud EG; Gonzalez M; Saba S; Jackson KP; Reece T; Gu J; Pokorney SD; Granger CB; Hess PL; Mark DB; Stevenson WG
    J Cardiovasc Electrophysiol; 2015 Feb; 26(2):151-7. PubMed ID: 25332150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials.
    Patel D; Hasselblad V; Jackson KP; Pokorney SD; Daubert JP; Al-Khatib SM
    J Interv Card Electrophysiol; 2016 Mar; 45(2):111-7. PubMed ID: 26695501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
    Arenal Á; Ávila P; Jiménez-Candil J; Tercedor L; Calvo D; Arribas F; Fernández-Portales J; Merino JL; Hernández-Madrid A; Fernández-Avilés FJ; Berruezo A
    J Am Coll Cardiol; 2022 Apr; 79(15):1441-1453. PubMed ID: 35422240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of persistent ventricular tachycardia: Drugs or ablation?
    MacIntyre CJ; Sapp JL
    Trends Cardiovasc Med; 2017 Oct; 27(7):506-513. PubMed ID: 28625728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular Tachycardia and ICD Therapy Burden With Catheter Ablation Versus Escalated Antiarrhythmic Drug Therapy.
    Samuel M; Healey JS; Nault I; Sterns LD; Essebag V; Gray C; Hruczkowski T; Gardner M; Parkash R; Sapp JL
    JACC Clin Electrophysiol; 2023 Jun; 9(6):808-821. PubMed ID: 37380314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs.
    Sapp JL; Wells GA; Parkash R; Stevenson WG; Blier L; Sarrazin JF; Thibault B; Rivard L; Gula L; Leong-Sit P; Essebag V; Nery PB; Tung SK; Raymond JM; Sterns LD; Veenhuyzen GD; Healey JS; Redfearn D; Roux JF; Tang AS
    N Engl J Med; 2016 Jul; 375(2):111-21. PubMed ID: 27149033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).
    Parkash R; Nault I; Rivard L; Gula L; Essebag V; Nery P; Tung S; Raymond JM; Sterns L; Doucette S; Wells G; Tang ASL; Stevenson WG; Sapp JL
    Circ Arrhythm Electrophysiol; 2018 Jan; 11(1):e005663. PubMed ID: 29305400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
    Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
    Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic decision tree for patients with sustained ventricular tachyarrhythmias or aborted cardiac arrest: a critical review of the Antiarrhythmics Versus Implantable Defibrillator trial and the Canadian Implantable Defibrillator Study.
    Farré J; Cabrera JA; Romero J; Rubio JM
    Am J Cardiol; 2000 Nov; 86(9A):44K-51K. PubMed ID: 11084100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term benefit of first-line peri-implantable cardioverter-defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients.
    Acosta J; Cabanelas N; Penela D; Fernández-Armenta J; Andreu D; Borràs R; Korshunov V; Cabrera M; Vasanelli F; Arbelo E; Guasch E; Martínez M; Tolosana JM; Mont L; Berruezo A
    Europace; 2017 Jun; 19(6):976-982. PubMed ID: 27353322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?
    Wichter T; Paul TM; Eckardt L; Gerdes P; Kirchhof P; Böcker D; Breithardt G
    Herz; 2005 Mar; 30(2):91-101. PubMed ID: 15875097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease.
    Martinez BK; Baker WL; Konopka A; Giannelli D; Coleman CI; Kluger J; Cronin EM
    Heart Rhythm; 2020 Jan; 17(1):e206-e219. PubMed ID: 31082362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.